APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 6
AUG'83 - FEB'84



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (◆) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

Because we are converting to a new automated data processing system, cumulative counts shown for the quarter ending January 1984, represent approximate values. Accurate quarterly values will be shown in Cumulative Supplement 7. Monthly values shown in Supplement 6 for February 1984, are accurate.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

Former Applicant (Name)	New Applicant (Name)	New Abbreviated Name
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES CORP	OPTOPICS LABS

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '83 (BASELINE)	OCT '83	JAN '84 (SEE SPECIAL NOTE A.)
DRUG PRODUCTS LISTED	6679	6783	6854
SINGLE SOURCE	1908 (28.6)	1915 (28.2%)	1925 (28.1%)
MULTISOURCE(1)	4771 (71.4)	4868 (71.8%)	4929 (71.9%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)	3947 (57.6%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)	972 (14.2%)
EXCEPTIONS(2)	10 (0.1%)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2	8
NUMBER OF APPLICANTS	304	310	309

B. ACTIVITY FOR SUPPLEMENT NUMBER 6

	FEB '84	CUMULATIVE
DRUG PRODUCTS ADDED:	28	28
NEWLY APPROVED	28	28
DESI EFFECTIVE	0	0
REMARKETED	0	0
DRUG PRODUCTS REMOVED:	7	7
WITHDRAWN APPROVAL	0	0
RX TO OTC SWITCH	0	0
DISCONTINUED MARKETING	9	9
NET GAIN IN DRUG PRODUCTS	21	21
SINGLE SOURCE PRODUCTS APPROVED	4	4
MULTISOURCE DRUG PRODUCTS APPROVED	24	24
NEW MOLECULAR ENTITIES APPROVED:	0	0
AS THE ENTITY	0	0
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	0

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE I-5 OF THE LIST)

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL

	ACETAMINOPHEN W/ CODEINE #3		
AA	LEMMON	300MG;30MG*	
	TYLENOL W/ CODEINE NO. 3		
AA	MCNEIL PHARM	300MG;30MG	

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE		
>_ADD_> AA	DURAMED PHARMS	300MG;15MG*	
>_ADD_> AA		300MG;30MG*	
>_ADD_> AA		300MG;60MG*	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL

	CODAGET	
AA	HALSEY DRUG	325MG;5MG*
	/PERCOCET-5/	
	PERCOCET	

/ACETAMINOPHEN; PHENACETIN; PHENYLPROPANOLAMINE HYDROCHLORIDE; PHENYLTOLOXAMINE CITRATE/(PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION

/RADIOIODINATED SERUM ALBUMIN (HUMAN) (HSA) I-131/

/MALLINCKRODT/	/6.7-250 UCI/ML/	

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION

NEOPHAM 6.5%		
CUTTER-VITRUM	6.5%*	

AMINOPHYLLINE (PAGE 3-8)

/LIQUID; ORAL/

SOLUTION; ORAL

	AMINOPHYLLINE	
AA	BAY LABORATORIES	105MG/5ML*
AA	ROXANE LABORATORIES	105MG/5ML*

AMINOPHYLLINE (PAGE 3-8)

TABLET; ORAL

	AMINOPHYLLINE	
BD	BARR LABORATORIES	100MG*
BD		200MG*
AB	VANGARD LABS/MWM	100MG*
AB		200MG*

/AMPHETAMINE SULFATE/(PAGE 3-13)

/CAPSULE, CONTROLLED RELEASE; ORAL

/BENZEDRINE/		
/SKAF. LABORATORIES/	/15MG/	

/TABLET; ORAL/

/BENZEDRINE/		
/SKAF. LABORATORIES/	/5MG/	
	/10MG/	

AMPICILLIN TRIHYDRATE; PROBENECID (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN-PRB	
AB	BRISTOL LABS/B-M	EQ 3.5GM BASE/BOT;1GM/BOT
	PROBAMPACIN	
AB	BIOCRAFT LABS	EQ 3.5GM BASE/BOT;1GM/BOT

ASPIRIN; BUTALBITAL (PAGE 3-15)

TABLET; ORAL

	AXOTAL	
	ADRIA LABORATORIES	650MG;50MG*

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)

TABLET; ORAL

	ASPIRIN AND CAFFEINE W/ BUTALBITAL	
AB	PUREPAC/KALIPHARMA	325MG;50MG;40MG*
	BUTALBITAL W/ ASPIRIN & CAFFEINE	
AB	BOOTS LABORATORIES	325MG;50MG;40MG*

/ASPIRIN; BUTALBITAL; CAFFEINE; PHENACETIN/(PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE (PAGE 3-15)

CAPSULE; ORAL
SYNALGOS-DC
IVES LABS/AMHO 356.4MG;30MG;16MG*

/ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE/
(PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
DARVON COMPOUND-65
AA ELI LILLY INDSTRS/PR 389MG;32.4MG;65MG
PROPOXYPHENE COMPOUND 65
AA LEMMON 389MG;32.4MG;65MG*
SK-65 COMPOUND
AA SK&F LABORATORIES 389MG;32.4MG;65MG*

ASPIRIN; CARISOPRODOL (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND
WALLACE PHARMS/C-W 325MG;200MG*

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND W/ CODEINE
WALLACE PHARMS/C-W 325MG;200MG;16MG*

ASPIRIN; HYDROCODONE BITARTRATE (PAGE 3-16)

TABLET; ORAL
VICOPRIN
KNOLL PHARMACEUTICAL 500MG;5MG*

ATRACURIUM BESYLATE (PAGE 3-16)

INJECTABLE; INJECTION
TRACRIUM
BURROUGHS WELLCOME 10MG/ML*

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-17)

LIQUID; ORAL
> DLT > /LOMOTIL/
> DLT >/AA/ /COMD LABORATORIES/ /0.025MG/5ML;2.5MG/5ML/

/AZURESIN/(PAGE 3-18)

/GRANULE; ORAL/
/DIAGNEX BLUE/
/ER SQUIBB AND SONS/ /EA/PACKET/

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
SPECTROBID
PFIZER LABS/PFIZER 800MG*

BENTIROMIDE (PAGE 3-19)

SOLUTION; ORAL
CHYMEX
ADRIA LABORATORIES 500MG/7.5ML*

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL
/PROAQUA/
/BP/ /REID-PROVIDENT LABS//50MG/

BENZTROPINE MESYLATE (PAGE 3-20)

TABLET; ORAL
BENZTROPINE MESYLATE
BP QUANTUM PHARMICS 0.5MG*
BP 1MG*
BP 2MG*
COGENTIN
BP MS&D/MERCK 0.5MG
BP 1MG
BP 2MG

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*

LOTION; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
AB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
AB SCHERING EQ 0.1% BASE

> ADD > BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
(PAGE 3-22)

> ADD > SYRUP; ORAL
> ADD > AMBENYL
> ADD > MARION LABORATORIES 12.5MG/5ML;10MG/5ML

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL
BROMPHENIRAMINE MALEATE
/AA/ /BOLAR PHARMACEUTICAL/ 4MG/

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION
MARCAINE HCL W/ EPINEPHRINE
AP BREON LABS/STERLING 0.5%;0.0091MG/ML
AP 0.75%;0.0091MG/ML
SENSORCAINE
AP ASTRA HOSP PHARM 0.5%;0.0091MG/ML*
AP 0.75%;0.0091MG/ML*

BUTABARBITAL SODIUM (PAGE 3-24)

CAPSULE; ORAL
BUTICAPS
/MCNEIL LABORATORIES/ /15MG/
/30MG/
/50MG/
/100MG/
WALLACE LABS/C-H 15MG
30MG
50MG
100MG

ELIXIR; ORAL
/BUTABARBITAL SODIUM/
/AA/ /WEST-WARD/ /33MG/5ML/
BUTALAN
/AA/ LANNETT 33.3MG/5ML

/CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETIN/
(PAGE 3-24)

/TABLET; ORAL/
/SOMA COMPOUND W/ CODEINE/
/WALLACE PHARMS/C-H/ /200MG;200MG;16MG;160MG/

/CAFFEINE; CARISOPRODOL; PHENACETIN/(PAGE 3-25)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

CAFFEINE; ERGOTAMINE TARTRATE (PAGE 3-25)

SUPPOSITORY; RECTAL
CAFERGOT
BR SANDOZ PHARMS/SANDOZ 100MG;2MG
WIGRAINE
BR ORGANON/AKZONA 100MG;2MG*

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 510MG/100ML;30GM/100ML;
200MG/100ML;9.2GM/100ML;
9.6GM/100ML*
510MG/100ML;30GM/100ML;
200MG/100ML;9.4GM/100ML;
11GM/100ML*

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
AM MCGAW/AM HOSP — 510MG/100ML;50GM/100ML
200MG/100ML;9.2GM/100ML;
9.6GM/100ML*
510MG/100ML;50GM/100ML;
200MG/100ML;9.4GM/100ML;
11GM/100ML*

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
DIALYTE W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AM MCGAW/AM HOSP — 26MG/100ML;2.5GM/100ML;
15MG/100ML;560MG/100ML;390MG/100ML*

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE (PAGE 3-27)

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
AM MCGAW/AM HOSP — 35MG/100ML;30MG/100ML;
74MG/100ML;640MG/100ML;
500MG/100ML;74MG/100ML*

CEFIZOXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
CEFIZOX
SK&F LABORATORIES — EQ 1GM BASE/VIAL*
EQ 2GM BASE/VIAL*

CEFUROXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
ZINACEF
GLAXO — EQ 750MG BASE/VIAL*
EQ 1.5GM BASE/VIAL*

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION
KEFLIN
AP ELI LILLY — EQ 1GM BASE/VIAL
AP — EQ 2GM BASE/VIAL

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION
SEFFIN
AP GLAXO — EQ 1GM BASE/VIAL*
AP — EQ 2GM BASE/VIAL*
EQ 10GM BASE/VIAL*

CEPHALOTHIN SODIUM; DEXTROSE (PAGE 3-31)

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
TRAVENOL LABS — EQ 20MG BASE/ML;50MG/ML*
EQ 40MG BASE/ML;50MG/ML*

CEPHALOTHIN SODIUM; SODIUM CHLORIDE (PAGE 3-31)

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
TRAVENOL LABS — EQ 20MG BASE/ML;9MG/ML*
EQ 40MG BASE/ML;9MG/ML*

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL
LIBRELEASE
HOFFMANN-LA ROCHE — 30MG*

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /BOOTS PHARMACEUTICAL/ 5MG/
/AB/ 10MG/
/AB/ 25MG/

CHLOROPROCAINE HYDROCHLORIDE (PAGE 3-34)

INJECTABLE; INJECTION
NESACAINE
> DLT > /PENNALT PHARM/ /1%/
> DLT > /2%/
> ADD > ASTRA PHARM PRODS 1%
> ADD > 2%
NESACAINE-CE
> DLT > /PENNALT PHARM/ /2%/
> DLT > /3%/
> ADD > ASTRA PHARM PRODS 2%
> ADD > 3%

CHLOROTHIAZIDE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE
AB CHELSEA LABORATORIES 250MG*
AB 500MG*

CHLOROTHIAZIDE; RESERPINE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE AND RESERPINE
BP WEST-WARD 250MG;0.125MG*
BP 500MG;0.125MG*

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
/AA/ /TONNE, PAULSEN/ /4MG/

CHLORPROPAMIDE (PAGE 3-38)

TABLET; ORAL
CHLORPROPAMIDE
>ADD> AB PAR PHARMACEUTICAL 100MG*
>ADD> AB 250MG*
DIABINESE
>ADD> AB PFIZER LABS/PFIZER 100MG

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL
CHLORTHALIDONE
AB PUREPAC/KALIPHARMA 50MG*

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL
CHLORZOXAZONE
AA PAR PHARMACEUTICAL 250MG*

CHYMOPAPAIN (PAGE 3-39)

INJECTABLE; INJECTION
DISCASE
TRAVENOL LABS 12,500 UNITS/VIAL*

CIMETIDINE (PAGE 3-39)

TABLET; ORAL
TAGAMET
SK&F LAB 400MG*

CLOTRIMAZOLE (PAGE 3-41)

>ADD> LOTION; TOPICAL
>ADD> LOTRIMIN
>ADD> SCHERING 1%*

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
/REPOSITORY CORTICOTROPIN/
/BC/ /WYETH LABS/AMHO/ /40 UNITS/ML/
/BC/ /80 UNITS/ML/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
CYANOCOBALAMIN
>ADD> AP SOLOPAK/MPL 1MG/ML*
DODECAMIN
AP MAURRY BIOLOGICAL 1MG/ML*
REDISOL
/AP/ MS&D/MERCK /6.1MG/ML/
SYTOBEX
/AP/ PARKE DAVIS/W-L /6.1MG/ML/

CYCLOSPORINE (PAGE 3-46)

INJECTABLE; INJECTION
SANDIMMUNE
SANDOZ PHARMS/SANDOZ 50MG/ML*

SOLUTION; ORAL
SANDIMMUNE
SANDOZ PHARMS/SANDOZ 100MG/ML*

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)

TABLET; ORAL
CYPROHEPTADINE HCL
AA DURAMED PHARMS 4MG*
>ADD> AA PIONEER PHARMS 4MG*

DAPSONE (PAGE 3-47)

TABLET; ORAL
/AVLOSULFON/
/BP/ /AYERST LABS/AMHO/ /25MG/
/BP/ /100MG/
DAPSONE
/BP/ JACOBUS PHARM 25MG
/BP/ 100MG

DESOXIMETASONE (PAGE 3-49)

OINTMENT; TOPICAL
TOPICORT
HOECHST-ROUSSEL 0.25%M

DEXAMETHASONE (PAGE 3-49)

SOLUTION; ORAL
DEXAMETHASONE
ROXANE LABORATORIES 0.5MG/5MLM
DEXAMETHASONE INTENSOL
ROXANE LABORATORIES 0.5MG/0.5MLM

TABLET; ORAL
DECADRON
BP MS&D/MERCK 6MG
DEXAMETHASONE
BP PAR PHARMACEUTICAL 6MGM
BP ROXANE LABORATORIES 6MGM
1MGM

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)

INJECTABLE; INJECTION
DEXAMETHASONE
AP INVENEX LABS/DEXTER EQ 4MG PHOSPHATE/MLM
AP EQ 10MG PHOSPHATE/MLM
DEXAMETHASONE SODIUM PHOSPHATE
> ADD > AP INTL MEDICATION SYS EQ 20MG PHOSPHATE/MLM
/HEXADROL PHOSPHATE/
HEXADROL
AP ORGANON/AKZONA EQ 4MG PHOSPHATE/ML
> ADD > AP EQ 20MG PHOSPHATE/ML

SOLUTION/DROPS; OPHTHALMIC
DEXAIR
AT PHARMAFAIR EQ 0.1% PHOSPHATEM
DEXAMETHASONE SODIUM PHOSPHATE
AT BARNES-HIND PHARMS EQ 0.1% PHOSPHATE

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
/DOPAMINE HCL IN DEXTROSE 5%/
DOPAMINE HCL
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
AP 5GM/100ML;160MG/100ML
DOPAMINE HCL IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100MLM
AP 5GM/100ML;160MG/100MLM
5GM/100ML;320MG/100MLM

DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

INJECTABLE; INJECTION
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
TRAVENOL LABS 5GM/100ML;4,000 UNITS/100MLM

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION
/DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM/
DIATRIZOATE-60

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

TABLET; ORAL
DIETHYLPROPION HCL
AA CAMALL 25MGM

DIMENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION
DIMENHYDRINATE
/AP/ /INTL MEDICATION SYS/ /50MG/ML/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL
SK-DIPHENHYDRAMINE
/AA/ SK&F LABORATORIES /25MG/

ELIXIR; ORAL
BELIX
AA HALSEY DRUG 12.5MG/5MLM
DIBENIL
AA HR CENCI LABS 12.5MG/5MLM

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

ELIXIR; ORAL
DIPHENHYDRAMINE HCL
>DLT >/AA/ /CORD LABORATORIES/ /12.5MG/5ML/
/SK-DIPHENHYDRAMINE/
/AA/ /SKAF LABORATORIES/ /12.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL
DISULFIRAM
BX CHELSEA LABORATORIES 250MG*
BX 500MG*
BX SIDMAK LABORATORIES 250MG*
BX 500MG*

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
AB CHELSEA LABORATORIES EQ 50MG BASE
AB HEATHER DRUG EQ 50MG BASE*
AB EQ 100MG BASE*
AB PAR PHARMACEUTICAL EQ 100MG BASE*
AB PUREPAC/KALIPHARMA EQ 50MG BASE*
AB EQ 100MG BASE*

INJECTABLE; INJECTION
DOXY 100
AP LYPHO-MED EQ 100MG BASE/VIAL*
DOXY 200
AP LYPHO-MED EQ 200MG BASE/VIAL*
DOXYCYCLINE
AP ELKINS-SINN EQ 100MG BASE/VIAL*
AP EQ 200MG BASE/VIAL*
VIBRAMYCIN
AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

TABLET; ORAL
DOXYCYCLINE HYCLATE
AB HEATHER DRUG EQ 100MG BASE*

DROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION
INNOVAR
/JANSSEN PHARM/ /2.5MG/ML;0.05MG/ML/
JANSSEN PHARMA 2.5MG/ML;EQ 0.05MG BASE/ML

DYCLONINE HYDROCHLORIDE (PAGE 3-64)

SOLUTION; TOPICAL
DYCLONE
>DLT > /MERRELL DOW/DOW CHEM/0.5%/
>DLT > /1%/
>ADD > ASTRA PHARM PRODS 0.5%
>ADD > 1%

ECHOTHIOPHATE IODIDE (PAGE 3-65)

POWDER FOR RECONSTITUTION; OPHTHALMIC
/ECHODIDE/
/AT/ /ALCON LABORATORIES/ /0.03%/
/AT/ /0.06%/
/AT/ /0.125%/
/AT/ /0.25%/
PHOSPHOLINE IODIDE
/AT/ AYERST LABS/AMHO 0.03%
/AT/ 0.06%
/AT/ 0.125%
/AT/ 0.25%

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 0.01MG/ML;2%*
AP 0.02MG/ML;2%*

ERGOLOID MESYLATES (PAGE 3-66)

CAPSULE; ORAL
/HYDERGINE/
HYDERGINE LC

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC
ERYTHROMYCIN
AT E FOUGERA/BYK-GLDN 5MG/GM*
AT PHARMADERM/BYK-GLDN 5MG/GM*
ILOTYCIN
AT DISTA PRODS/LILLY 5MG/GM

ESTRADIOL (PAGE 3-69)

>ADD > CREAM; VAGINAL
>ADD > ESTRACE
>ADD > MEAD JOHNSON/B-M 0.01%*

ETOPOSIDE (PAGE 3-74)

INJECTABLE; INJECTION
VEPESID
BRISTOL LABS/B-M 20MG/ML*

FENTANYL CITRATE (PAGE 3-75)

INJECTABLE; INJECTION
SUBLIMAZE
/JANSSEN PHARMA/ /0.05MG/ML/
JANSSEN PHARMA EQ 0.05MG BASE/ML

FLUOCINOLONE ACETONIDE (PAGE 3-76)

CREAM; TOPICAL
FLUOCET
AT NMC LABORATORIES 0.01%*
AT 0.025%*

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
>_ADD_> AT PHARMAFAIR 0.025%*

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
AT BAY LABORATORIES 0.01%*
>_ADD_> AT PHARMAFAIR 0.01%*

FLUOXYMESTERONE (PAGE 3-77)

TABLET; ORAL
FLUOXYMESTERONE
BP BOLAR PHARMACEUTICAL 2MG*
BP 5MG*
BP 10MG*
BP COLMED LABORATORIES 10MG*

FUROSEMIDE (PAGE 3-79)

INJECTABLE; INJECTION
FUROSEMIDE
AP NATCON CHEMICAL 10MG/ML*

TABLET; ORAL
FUROSEMIDE
AB BARR LABORATORIES 40MG*
>_ADD_> AB INTL MEDICATION SYS 20MG*
>_ADD_> AB 40MG*
AB ROXANE LABORATORIES 20MG*
AB 40MG*
AB ZENITH LABORATORIES 20MG*
AB 40MG*

GENTAMICIN SULFATE (PAGE 3-79)

CREAM; TOPICAL
GENTAFAIR
AT PHARMAFAIR EQ 1MG BASE/GM*
GENTAMICIN SULFATE
AT NMC LABORATORIES EQ 1MG BASE/GM*

INJECTABLE; INJECTION
GENTAMICIN SULFATE
AP ABBOTT LABORATORIES EQ 60MG BASE/100ML*
AP EQ 70MG BASE/100ML*
AP EQ 80MG BASE/100ML*
AP EQ 90MG BASE/100ML*
AP EQ 100MG BASE/100ML*
AP EQ 1.2MG BASE/ML*
AP EQ 1.4MG BASE/ML*
AP EQ 1.6MG BASE/ML*
AP EQ 1.8MG BASE/ML*
AP EQ 2MG BASE/ML*
AP EQ 10MG BASE/ML*
AP EQ 40MG BASE/ML*
AP LYPHO-MED EQ 40MG BASE/ML*
GENTAMICIN SULFATE IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES EQ 60MG BASE/100ML*
AP EQ 70MG BASE/100ML*
AP EQ 80MG BASE/100ML*
AP EQ 90MG BASE/100ML*
AP EQ 100MG BASE/100ML*
AP EQ 1.2MG BASE/ML*
AP EQ 1.4MG BASE/ML*
AP EQ 1.6MG BASE/ML*
AP EQ 1.8MG BASE/ML*
AP EQ 2MG BASE/ML*

OINTMENT; TOPICAL
GENTAMICIN SULFATE
AT THAMES PHARMACAL EQ 1MG BASE/GM*

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION
/ANTUITRIN S/
/AP/ /PARKE-DAVIS/A-I/ /5,000 UNITS/VIAL/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL
FULVICIN P/G 165
AB SCHERING 165MG

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL
FULVICIN P/G 330
AB SCHERING 330MG
GRISACTIN ULTRA
AB AYERST LABS/AMHO 165MG*
AB 330MG*

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION
HEPARIN SODIUM
AP NATCON CHEMICAL 1,000 UNITS/ML*

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION
HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT LABORATORIES 100 UNITS/ML;4.5MG/ML*
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT LABORATORIES 10,000 UNITS/100ML;450MG/100ML*
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100ML*
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%
ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100ML*
10,000 UNITS/100ML;450MG/100ML*
HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT LABORATORIES 1,000 UNITS/100ML;900MG/100ML*
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT LABORATORIES 10,000 UNITS/100ML;900MG/100ML*
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100ML*
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%
ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100ML*

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL
HOMAPIN-10
/AA/ MISSION PHARMACAL 10MG
/SEDS-TENS SE/
/AA/ /LEMMON/ /10MG/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

TABLET; ORAL
HYDRALAZINE HCL
AA PAR PHARMACEUTICAL 100MG*
AA PUREPAC/KALIPHARMA 50MG*

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-87)

TABLET; ORAL
/R-HCTZ-H/
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL
RESERPINE, HYDRALAZINE HCL, AND HYDROCHLOROTHIAZIDE
BP REID-PROVIDENT LABS 25MG;15MG;0.1MG*

HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-89)

TABLET; ORAL
RESERPINE AND HYDROCHLOROTHIAZIDE
BP CORD LABORATORIES 50MG;0.125MG*

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-89)

TABLET; ORAL
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
AB PUREPAC/KALIPHARMA 25MG;25MG*

HYDROCORTISONE (PAGE 3-90)

CREAM; TOPICAL
ELDECORT
/AT/ ELDER PHARMS /0.5%/
HYDROCORTISONE
AT BAY LABORATORIES 1%*
AT 2.5%*

LOTION; TOPICAL
/DELACORT/
/AT/ /MERICON INDUSTRIES/ /0.5%/
GLY-CORT
AT HERAN PHARMACEUTICAL 1%*
HYDROCORTISONE
AT MERICON INDUSTRIES 0.5%
/AT/ /JOHN PAULSEN/ /0.5%/

OINTMENT; TOPICAL
HYDROCORTISONE
AT BAY LABORATORIES 1%*
AT 2.5%*

/SOLUTION/DROPS, OPHTHALMIC/
/OPTEF/
/UPJOHN/ /0.5%/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-92)

SOLUTION/DROPS; OTIC
NEO-OTOSOL-HC
AT CARTER-GLOGAU LABS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML*

HYDROCORTISONE ACETATE (PAGE 3-93)

CREAM; TOPICAL
HYDROCORTISONE ACETATE
/AT/ /TOWNE, PAULSEN/ /1%/

LOTION; TOPICAL
DRICORT
/AT/ INGRAM PHARM 0.5%
/HYDROCORTISONE ACETATE/
/AT/ /TOWNE, PAULSEN/ /0.5%/

/SUSPENSION/DROPS, OPHTHALMIC, OTIC/
/HYDROCORTONE/
/MSD/MERCK/ /2.5%/

HYDROCORTISONE VALERATE (PAGE 3-95)

OINTMENT; TOPICAL
WESTCORT
WESTWOOD PHARMS 0.2%*

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL
HYDROFLUMETHIAZIDE AND RESERPINE
BP COLMED LABORATORIES 50MG;0.125MG*

HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)

INJECTABLE; INJECTION
DILAUDID-HP
KNOLL PHARMACEUTICAL 10MG/ML*

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL
HYDROXYZINE HCL
AB BARR LABORATORIES 10MG*
AB DANBURY PHARMACAL 10MG*
AB 25MG*
AB 50MG*

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMOATE
>ADD> AB DURAMED PHARMS EQ 25MG HCL*
>ADD> AB EQ 50MG HCL*
>ADD> AB EQ 100MG HCL*
AB VANGARD LABS/M&M EQ 25MG HCL*
AB EQ 50MG HCL*

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
/ANTIPRESS/
/BP/ /LEMMON/ /25MG/
/IMAVATE/
/AG/ /A.H. ROBINS/ /25MG/
/AB/ /50MG/
IMIPRAMINE HCL
AB PAR PHARMACEUTICAL 10MG*
AB 25MG*
AB 50MG*

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
AM INTL MEDICATION SYS 0.167%
AM ROXANE LABORATORIES 0.167%*
AM TRAVENOL LABS 0.25%*

ISONIAZID (PAGE 3-101)

SYRUP; ORAL
ISONIAZID
AA CAROLINA MED PRODS 50MG/5ML*
RIMIFON
AA HOFFMANN-LA ROCHE 50MG/5ML

ISOPROTERENOL HYDROCHLORIDE (PAGE 3-102)

SOLUTION; INHALATION
ISOPROTERENOL HCL
>DLT>/AM/ /INTL MEDICATION SYS/ /0.5%/

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION
KANAMYCIN SULFATE
AP INTL MEDICATION SYS EQ 500MG BASE/2ML*
AP EQ 1GM BASE/3ML*
KANTREX
/AP/ /BRISTOL LABS/B-M/ /75MG/2ML/
/AP/ /500MG/2ML/
/AP/ /1GM/3ML/
AP BRISTOL LABS/B-M EQ 75MG BASE/2ML
AP EQ 500MG BASE/2ML
AP EQ 1GM BASE/3ML

LIDOCAINE HYDROCHLORIDE (PAGE 3-104)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 2%*

METHOCARBAMOL (PAGE 3-117)

TABLET; ORAL
METHOCARBAMOL
> ADD > AA ROXANE LABORATORIES 500MG*
> ADD > AA 750MG*

METHYLPREDNISOLONE (PAGE 3-120)

TABLET; ORAL
METHYLPREDNISOLONE
> ADD > BP DURAMED PHARMS 4MG*

METHYLTESTOSTERONE (PAGE 3-121)

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE
/BP/ /JOHNE PAULSEN/ /10MG/

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
METRONIDAZOLE
AP ABBOTT LABORATORIES 500MG/100ML*
METRONIDAZOLE IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 500MG/100ML*
METRO I.V. IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 500MG/100ML*

METRONIDAZOLE (PAGE 3-122)

TABLET; ORAL
METRONIDAZOLE
AB PAR PHARMACEUTICAL 250MG*
AB 500MG*

NANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION
NANDROLONE DECANOATE
AO CARTER-GLOGAU 200MG/ML*
AO LEMMON 100MG/ML
50MG/ML
AO LYPHO-MED 100MG/ML*
AO 200MG/ML*
AO MAURRY BIOLOGICAL 100MG/ML*

NAPHAZOLINE HYDROCHLORIDE (PAGE 3-125)

SOLUTION/DROPS; OPHTHALMIC
VASOCON
> DLT >/AT/ /SMITH PR/COOPERVISN/ /0.12/
> ADD > AT COOPERVISION PHARMS 0.1%

NICOTINE RESIN COMPLEX (PAGE 3-127)

GUM, CHEWING; ORAL
NICORETTE
MERRELL DOW/DOW CHEM EQ 2MG BASE*

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
AP G POHL-BOSKAMP 5MG/ML*
1MG/ML*
TRIDIL
AM CRITICAL CARE/AHS 0.5MG/ML*

NYSTATIN (PAGE 3-129)

OINTMENT; TOPICAL
NYSTATIN
> ADD > AT CLAY-PARK LABS 100,000 UNITS/GM*

POWDER; ORAL
NILSTAT
LEDERLE LABS/AM CYAN 100%*

NYSTATIN (PAGE 3-129)

TABLET; ORAL
NYSTATIN

AA	PAR PHARMACEUTICAL	500,000 UNITS*

TABLET; VAGINAL
NYSTATIN

AT	E FOUGERA/BYK-GLDN	100,000 UNITS*
AT	PHARMADERM/BYK-GLDN	100,000 UNITS*

OXPRENOLOL HYDROCHLORIDE (PAGE 3-131)

CAPSULE; ORAL
TRASICOR

CIBA/CIBA-GEIGY	20MG*
	40MG*
	80MG*
	160MG*

OXTRIPHYLLINE (PAGE 3-131)

ELIXIR; ORAL
OXTRIPHYLLINE

BAY LABORATORIES	100MG/5ML*

SYRUP; ORAL
CHOLEDYL

AA	PARKE-DAVIS/W-L	50MG/5ML

OXTRIPHYLLINE PEDIATRIC

AA	BAY LABORATORIES	50MG/5ML*

TABLET, ENTERIC COATED; ORAL
CHOLEDYL

AB	PARKE-DAVIS/W-L	100MG
AB		200MG

OXTRIPHYLLINE

AB	BOLAR PHARMACEUTICAL	100MG*
AB		200MG*

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL
/OXYDOAG/

/AA/	/PARKE-DAVIS/W-L/	/EQ 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL
/PENICILLIN VK/

/AA/	/UPJOHN/	/EQ 125MG BASE/5ML/
/AA/		/EQ 250MG BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-138)

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	FERNDALE LABS	35MG*

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL
ADIPEX-P

AA	LEMMON	37.5MG*

DAPEX-37.5

AA	FERNDALE LABS	37.5MG*

PHENTERMINE HCL

AA	CAMALL	37.5MG*

POTASSIUM CHLORIDE (PAGE 3-143)

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

/AP/	TRAVENOL LABS	/1MEQ/ML/
/AP/		/2MEQ/ML/
/AP/		/4MEQ/ML/

PREDNISOLONE (PAGE 3-145)

TABLET; ORAL
PREDNISOLONE

/BX/	/REXALL DRUG/	/5MG/

PREDNISOLONE ACETATE (PAGE 3-146)

INJECTABLE; INJECTION
/FERNISOLONE/

/AP/	/FERNDALE LABS/	/25MG/ML/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC
/HYDELTRASOL/

/AT/	/MSD/MERCK/	/EQ 0.5% PHOSPHATE/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC

/AT/	/INFLAMASE/		
/AT/	/SMAP/PR/COOPERVISN/	/EQ 0.12 BASE/	
	INFLAMASE MILD		
AT	COOPERVISION PHARMS	EQ 0.11% PHOSPHATE	
	INFLAMASE FORTE		
/AT/	/SMAP/PR/COOPERVISN/	/EQ 0.82 BASE/	
AT	COOPERVISION PHARMS	EQ 0.9% PHOSPHATE	
	METRETON		
/AT/	SCHERING	EQ 0.5% PHOSPHATE	
> ADD >	PREDAIR		
> ADD > AT	PHARMAFAIR	EQ 0.11% PHOSPHATE*	
	PREDAIR FORTE		
AT	PHARMAFAIR	EQ 0.9% PHOSPHATE	
	PREDNISOLONE SODIUM PHOSPHATE		
/AT/	/BARNES-HIND PHARMS/	/0.12%/	
		/12/	
AT	BARNES-HIND PHARMS	EQ 0.11% PHOSPHATE	
AT		EQ 0.9% PHOSPHATE	
/AT/	/MAURRY BIOLOGICAL/	/EQ 0.12 BASE/	
/AT/		/EQ 0.82 BASE/	
AT	MAURRY BIOLOGICAL	EQ 0.11% PHOSPHATE	
AT		EQ 0.9% PHOSPHATE	

PREDNISOLONE TEBUTATE (PAGE 3-147)

INJECTABLE; INJECTION

	HYDELTRA-TBA		
> ADD > BP	MS&D/MERCK	20MG/ML	
> ADD >	PREDNISOLONE TEBUTATE		
> ADD > BP	CARTER-GLOGAU LABS	20MG/ML*	

PREDNISONE (PAGE 3-147)

TABLET; ORAL

	PREDNISONE	
BX	DURAMED PHARMS	5MG*
BX		10MG*
BX		20MG*

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL

	PROCAN	
/AB/	PARKE-DAVIS/W-L	/250MG/
/AB/		/500MG/

PROPANTHELINE BROMIDE (PAGE 3-153)

TABLET; ORAL

	PROPANTHELINE BROMIDE	
AA	PAR PHARMACEUTICAL	15MG*

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL

	PROPOXYPHENE HCL	
AA	RICHLYN LABORATORIES	65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL

	PROPYLTHIOURACIL	
/BD/	/MYLAN PHARMS/	/50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

SYRUP; ORAL

> ADD >	ACTAMIST		
> ADD > AA	HR CENCI LABS	30MG/5ML;1.25MG/5ML*	
	/PSEUDODINE/		
/AA/	/BAY LABORATORIES/	/30MG/5ML;1.25MG/5ML/	
	/TRIACIN/		
/AA/	/NATL PHARM MFG/BARRE/	/30MG/5ML;1.25MG/5ML/	
	TRIPOSED		
> ADD > AA	HALSEY DRUG	30MG/5ML;1.25MG/5ML*	

TABLET; ORAL

	/TRI-SUDD/	
/AA/	/MD PHARMACEUTICAL/	/60MG;2.5MG/
	/TRIPODRINE/	
/AA/	/DANBURY PHARMACAL/	/60MG;2.5MG/
	TRIPROLIDINE AND PSEUDOEPHEDRINE	
AA	BOLAR PHARMACEUTICAL	60MG;2.5MG*
/AA/	/WEST-WARD/	/60MG;2.5MG/
	TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL	
AA	CHELSEA LABORATORIES	60MG;2.5MG*

QUINIDINE GLUCONATE (PAGE 3-157)

TABLET, CONTROLLED RELEASE; ORAL

	QUINIDINE GLUCONATE	
AB	ROXANE LABORATORIES	324MG*

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
AB VITARINE/WEST CHEM **300MG**

RESERPINE (PAGE 3-158)

TABLET; ORAL
/RAURINE/
/BP/ /ONEAL,JONES&FELDMAN//0.25MG/
RESERPINE
> DLT > /BP/ /CORD LABORATORIES/ /0.1MG/
> DLT > /BP/ /0.25MG/
/VIO-SERPINE/
/BP/ /RONELL LABORATORIES//0.1MG/
/BP/ /0.25MG/

SECOBARBITAL SODIUM (PAGE 3-160)

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA LANNETT **50MG**
SECONAL SODIUM
AA ELI LILLY **50MG**
AA **100MG**

SELENIUM SULFIDE (PAGE 3-161)

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT BAY LABORATORIES **2.5%**

SILVER SULFADIAZINE (PAGE 3-161)

CREAM; TOPICAL
/SILVER SULFADIAZINE/
SSD

/STYOSTEROL, ALPHA/(PAGE 3-161)

/SUSPENSION, ORAL/
/CYTELLIN/
/ELI LILLY/ /3GM/15ML/

SODIUM CHLORIDE (PAGE 3-162)

INJECTABLE; INJECTION
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
TRAVENOL LABS 3GM/100ML
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
TRAVENOL LABS 5GM/100ML

SODIUM POLYSTYRENE SULFONATE (PAGE 3-165)

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA ROXANE LABORATORIES **15GM/60ML**
SPS
AA CAROLINA MED PRODS **15GM/60ML**

SOMATROPIN (PAGE 3-165)

INJECTABLE; INJECTION
ASELLACRIN 2
SERONO LABS 2 IU/VIAL
/ASELLACRIN/
ASELLACRIN 10

SPIRONOLACTONE (PAGE 3-166)

TABLET; ORAL
SPIRONOLACTONE
AB PUREPAC/KALIPHARMA **25MG**

SULFACETAMIDE SODIUM (PAGE 3-167)

SOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE
/AT/ /KETCHUM LABORATORIES/**10%**/
/AT/ /**10%**/
AT OPTOPICS LABS **10%**
AT **30%**
SULF-10
> DLT >/AT/ /STERI-MED/COOPERVISION/ /**10%**/
> ADD > AT COOPERVISION PHARMS **10%**
SULFACEL-15
/AT/ /STERI-MED/KETCHUM/ /**15%**/
AT OPTOPICS LABS **15%**
SULFAIR FORTE
AT PHARMAFAIR **30%**

SULFINPYRAZONE (PAGE 3-169)

CAPSULE; ORAL
SULFINPYRAZONE
>ADD > AB VANGARD LABS/MWM 200MG*

SULFISOXAZOLE (PAGE 3-170)

>DLT > /CREAM; VAGINAL/
>DLT > /GANTRISIN/
>DLT >/AY/ /HOFFMANN-LA ROCHE/ /12%/
>DLT > /KORO-SULF/
>DLT >/AY/ /HOLLAND-RANTOS/ /12%/

TERBUTALINE SULFATE (PAGE 3-173)

TABLET; ORAL
BRICANYL
>DLT > /BP/ /ASTRA PHARM PRODS/ /2.5MG/
>DLT > /BP/ /5MG/
>ADD > BP MERRELL DOW/DOW CHEM 2.5MG
>ADD > BP 5MG

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION
TESTOSTERONE
CARTER-GLOGAU LABS 50MG/ML*

TETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

CAPSULE; ORAL
TETRACYCLINE HCL
/AB/ /LEMMON/ /250MG/

TABLET; ORAL
PANMYCIN
/AB/ UPJOHN /250MG/
SUMYCIN
/AB/ ER SQUIBB AND SONS 250MG

THALLOUS CHLORIDE, TL-201 (PAGE 3-175)

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
MEDI-PHYSICS 2MCI/ML

THEOPHYLLINE (PAGE 3-176)

(FOR CONTROLLED RELEASE PRODUCTS - SEE SPECIAL NOTE C.)

CAPSULE, CONTROLLED RELEASE; ORAL
SOMOPHYLLIN-CRT
BC FISONS 100MG
THEO-24
BC SEARLE/SEARLE PHARMS 100MG*
200MG*
300MG*

ELIXIR; ORAL
ELIXOMIN
AA HR CENCI LABS 80MG/15ML*

SOLUTION; ORAL
THEOLAIR
AA RIKER LABS/3M 80MG/15ML
THEOPHYLLINE
AA ROXANE LABORATORIES 80MG/15ML*

TABLET, CONTROLLED RELEASE; ORAL
THEOCONTIN
BC PURDUE FREDERICK 200MG*
/400MG/
THEO-DUR
BC KEY PHARMACEUTICALS 200MG
UNIPHYL
PURDUE FREDERICK 400MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL
THIORIDAZINE HCL
AA CORD LABORATORIES 30MG/ML*
AA 100MG/ML*
AA NATL PHARM MFG/BARRE 100MG/ML*

TABLET; ORAL
MELLARIL
AB SANDOZ PHARMS/SANDOZ 100MG
THIORIDAZINE HCL
AB BARR LABORATORIES 10MG*
AB 15MG*
AB 25MG*
AB 50MG*
AB 100MG*
AB BOLAR PHARMACEUTICAL 10MG*
AB 100MG*
AB CORD LABORATORIES 10MG*
AB 15MG*
AB 25MG*
AB 50MG*

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

TABLET; ORAL
THIORIDAZINE HCL

AB	DANBURY PHARMACAL	10MG*
AB		15MG*
AB		25MG*
AB		50MG*
AB	MYLAN PHARMS	100MG*
AB	PAR PHARMACEUTICAL	10MG*
AB		15MG*
AB		25MG*
AB		50MG*
AB		100MG*
AB	ZENITH LABORATORIES	100MG*

TIMOLOL MALEATE (PAGE 3-179)

TABLET; ORAL
BLOCADREN
MS&D/MERCK 5MG

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

AEROSOL; INHALATION
/ARISTOCORT/
/LEDERLE LABS/AM CYAN/0.25MG/INH/
AZMACORT
WILLIAM H RORER 0.25MG/INH

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	BAY LABORATORIES	0.025%*
AT		0.1%*
AT		0.5%*

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	BAY LABORATORIES	0.025%*
AT		0.1%*
AT		0.5%*

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-183)

TABLET; ORAL
/TRIAZINE/
TEP

TRIPELENNAMINE HYDROCHLORIDE (PAGE 3-185)

TABLET; ORAL
TRIPELENNAMINE HCL

/AA/	/WEST-WARD/	/50MG/

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL
/QUAD-RANDIN/
/AB/ /ELDER PHARMS/ /500MG/5ML/
/TRISEM/
/AB/ /BEECHAM LABS/BEECHAM/500MG/5ML/
/TRISUREID/
/AB/ /REID-PROVIDENT LABS//500MG/5ML/

TABLET; ORAL
/QUADRITS/
/AB/ /ELDER PHARMS/ /500MG/
/TRIPLE SULFA #2/
/AB/ /ZENITH LABORATORIES//500MG/

TROPICAMIDE (PAGE 3-186)

SOLUTION/DROPS; OPHTHALMIC
MYDRIAFAIR

AT	PHARMAFAIR	0.5%*
AT		1%*

/TYBAMATE/(PAGE 3-186)

/CAPSULE; ORAL/
/TYBATRAN/
/AH ROBINS/ /250MG/
/350MG/

VITAMIN A PALMITATE (PAGE 3-188)

CAPSULE; ORAL
/SOLVISYN A/
/AA/ /TOWNE PAULSEN/ /25,000 UNITS BASE/

WATER FOR INJECTION, STERILE (PAGE 3-189)

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	INVENEX LABS/DEXTER	100%*

>DLT > /AMINOPHYLLINE; PHENOBARBITAL; RACEPHEDRINE HYDROCHLORIDE/ (PAGE AD2)

>DLT > /TABLET; ORAL/
>DLT > /AMODRINE/
>DLT > /SEARLE PHARMS/ /100MG;8MG;25MG/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E (PAGE AD2)

INJECTABLE; INJECTION
MVC PLUS
ASCOT HOSP PHARMS 10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML; 4MG/ML;0.4MG/ML;0.36MG/ML; 0.3MG/ML;330 IU/ML;1 IU/ML

/BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/ELIXIR; ORAL/
/ELIXIR DINETAPP/
/AH ROBINS/ /4MG/5ML;5MG/5ML;5MG/5ML/

/TABLET, CONTROLLED RELEASE; ORAL/
/DINETAPP/
/AH ROBINS/ /12MG;15MG;15MG/

/CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE; ISOPROPAMIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/CAPSULE, CONTROLLED RELEASE; ORAL/
/TUSS-ORNADE/
/SKAF LABORATORIES/ /20MG;8MG;2.5MG;50MG/

/SOLUTION; ORAL/
/TUSS-ORNADE/
/SKAF LABORATORIES/ /5MG/5ML;2MG/5ML;0.75/5ML;15MG/5ML/

DICYCLOMINE HYDROCHLORIDE (PAGE AD3)

SYRUP; ORAL
BAYCYCLOMINE
BAY LABORATORIES 10MG/5ML

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL
DIPYRIDAMOLE
ASCOT HOSP PHARMS 50MG
DURAMED PHARMS 25MG
50MG
75MG
HALSEY DRUG 50MG
SUPERPHARM 50MG

ISOSORBIDE DINITRATE (PAGE AD5)

TABLET; ORAL
ISOSORBIDE DINITRATE
>ADD > BARR LABORATORIES 30MG

/METHANDROSTENOLONE/ (PAGE AD6)

/TABLET; ORAL/
/METHANDROSTENOLONE/
/PAR PHARMACEUTICAL/ /2.5MG/ /5MG/

CURRENT STATUS - INEFFECTIVE

>_DLT_>/AMBENY EXPECTORANT/ /MARION LABORATORIES/
>_DLT_> /AMMONIUM CHLORIDE; BROMODIPHENHYDRAMINE HYDROCHLORIDE;/
>_DLT_> /CODEINE SULFATE; DIPHENHYDRAMINE HYDROCHLORIDE; MENTHOL;/
>_DLT_> /POTASSIUM GUAIACOSULFONATE/

>_ADD_> AMODRINE SEARLE PHARMS
>_ADD_> AMINOPHYLLINE; PHENOBARBITAL; RACEPHEDRINE HYDROCHLORIDE

/CARBRITAL/ /PARKE-DAVIS/W-C/
/CARBROMAL; PENTOBARBITAL SODIUM/

/CLISTIN DA/ /MCNEIL PHARM/
/CARBINOXAMINE MALEATE/

DIMETAPP AH ROBINS
BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR DIMETAPP AH ROBINS
BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
PHENYLPROPANOLAMINE HYDROCHLORIDE

>_DLT_>/EQUANITRATE 16/ /WYETH LABS/AHHO/
>_DLT_> /MEPROBAMATE; PENTAERYTHRITOL TETRANITRATE/

>_DLT_>/EQUANITRATE 26/ /WYETH LABS/AHHO/
>_DLT_> /MEPROBAMATE; PENTAERYTHRITOL TETRANITRATE/

/FORMISTAL/ /CIBA/CIBA-GEIGY/
/DIMETHINDENE MALEATE/

>_ADD_> GANTRISIN HOFFMAN-LA ROCHE
>_ADD_> SULFISOXAZOLE

>_DLT_>/ISORDIL W/ PHENOBARBITAL/ /IVES LABS/AHHO/
>_DLT_> /ISOSORBIDE DINITRATE; PHENOBARBITAL/

>_ADD_> KORO-SULF HOLLAND-RANTOS
>_ADD_> SULFISOXAZOLE

METHANDROSTENOLONE PAR PHARMACEUTICAL
METHANDROSTENOLONE

TUSS-ORNADE SK&F LABORATORIES
CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE;
ISOPROPAMIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

☆ U.S. GOVERNEMNT PRINTING OFFICE: 1984-421-927:208